22 Nov 2024
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in combination with endocrine therapy for the treatment of pa
22 Nov 2024
Submission based on positive results from the Phase III ARANOTE trial which showed NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of progression or death in patients with metastatic hormone-sensitive prostate cancer (mHSPC) when compared to
22 Nov 2024
Lake Zurich, Ill., November 21, 2024 – Fresenius Kabi, an operating company of Fresenius, announced today it has submitted a 510(k) notification to the U.S. Food and Drug Administration seeking clearance of the Aurora Xi Plasmapheresis System software version 2.0. The Aurora Xi is Plas
22 Nov 2024
First RSV vaccine approved in Japan to help protect 50-59 year olds at increased risk due to certain underlying health conditions RSV infections can exacerbate these underlying health conditions and lead to severe outcomes, such as pneumonia, hospitalisation and death1 35 countries, including
22 Nov 2024
November 21, 2024 Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer Results bolster Company's rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patie
22 Nov 2024
Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients. Nov 21, 2024 Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transactio